Oncolytics Biotech Inc T.ONC

Endpoints on Merck kGAa

[m00nsh0ts]

https://endpts.com/merck-kgaa-spotlights-need-for-deals-to-shake-up-rd-with-external-partners-key-to-new-drugs/

[Noteable]

November 21, 2022 - "German healthcare company Merck KGaA wants to ramp up its R&D productivity with the goal of launching a new drug, or tacking on a new indication to an approved med, every one and a half years." https://endpts.com/merck-kgaa-spotlights-need-for-deals-to-shake-up-rd-with-external-partners-key-to-new-drugs/  Noteable 

[Noteable]

On October 06, 2022 and in a statement ahead of its capital markets day, the global conglomerate (MerckKGaA) said it will consider "larger-scale" acquisitions beginning in 2023. [MerckKGaA and Pfizer are partnered sponsors in ONCY's Bracelet-1 Phase 2 metastatic breast cancer study involving "Pelareorep" + Merck KGaA/Pfizer's immune checkpoint inhibitor "

[Noteable]

November 21, 2022 - MilliporeSigma, the US and Canadian life science division of Merck KGaA, is plunking down almost $300 million to boost biosafety testing in the US.   The company said it will invest $286 million to bulk up biosafety testing at its manufacturing site in Rockville, MD. The new, 250,000-square-foot facility expansion will extend its capacity for biosafety testing

[Noteable]

https://endpts.com/merck-kgaa-continues-expansion-with-285m-investment-in-2-new-projects-in-france-and-germany/